Fluorescent Guide Can ID Tumor Missed by Standard Lumpectomy

TUESDAY, May 23, 2023 (HealthDay News) -- For patients with stages 0 to 3 breast cancers, pegulicianine fluorescence-guided surgery (pFGS) can enhance the efficacy of lumpectomy surgery, according to a study published online April 27 in NEJM Evidence.

Barbara L. Smith, M.D., Ph.D., from Massachusetts General Hospital in Boston, and colleagues conducted a prospective trial to examine margin status with or without intraoperative pFGS for stages 0 to 3 breast cancers. Patients were randomly assigned 10:1 to pFGS or control groups to prevent surgeons from performing smaller than standard lumpectomies in anticipation of pFGS assistance. In patients undergoing pFGS, at sites of pegulicianine signal, additional pFGS-guided cavity margins were excised. The percentage of patients for whom pFGS-guided margins contained cancer, sensitivity, and specificity were examined as coprimary end points.

Originally published on consumer.healthday.com, part of the BLOX Digital Content Exchange.